Maze Therapeutics MAZE Insider Ownership

Updated Nov 5, 2026

Over the past year, MAZE insiders sold $24.96 million of stock (751.87K shares) on the open market and bought none.

• Behind Maze Therapeutics' open-market sales in the past 12 months were 6 insiders, and no insider bought.
• Harold Bernstein (President, R&D & CMO) was the top open-market seller of Maze Therapeutics over the past 12 months, with $9.46 million sold (262.89K shares) and the latest sale on October 1, 2026.
• The latest open-market trade on record is a sale of 34.5K shares for $1.04 million by Jason V. Coloma (Chief Executive Officer) on November 2, 2026.
• In transactions other than open-market trades, Maze Therapeutics insiders acquired 565.1K shares through option exercises and conversions and gave away 7.42K shares as gifts over the past 12 months.
• Business Quant data shows Maze Therapeutics insiders holding 6.05Mn shares in total in their latest Form 4 filings, or 10.26% of the 59Mn shares outstanding; that total is down 1.70% from 6.16Mn shares at the end of Q2 2026 and down 18.21% from 7.4Mn shares at the end of Q3 2025.
• Maze Therapeutics insiders hold 4.58Mn shares directly (75.77% of their total) and 1.47Mn shares (24.23%) indirectly, through entities such as trusts and partnerships.
• Per Business Quant, 7 insiders of MAZE hold shares, counting officers, directors and 10% owners who have filed a Form 4 in the past two years.
• MAZE's three largest insider shareholders, per their latest Form 4 filings, are Third Rock Ventures IV, L.P. (10% owner, 5.42Mn shares), Jonathan E. Lim (Director, 307.96K shares) and Jason V. Coloma (Chief Executive Officer, 227.23K shares).
• The holding of Third Rock Ventures IV, L.P. makes up 89.65% of all shares held by Maze Therapeutics insiders.
• Over the past 12 months, 17 insiders reported transactions in Maze Therapeutics stock in 64 Form 4 filings.
• This summary of Maze Therapeutics insider activity covers Form 4 filings through November 4, 2026.